keyword
MENU ▼
Read by QxMD icon Read
search

Sublingual immunotherapy

keyword
https://www.readbyqxmd.com/read/29146015/tablet-based-sublingual-immunotherapy-for-respiratory-allergy
#1
REVIEW
L Prieto
Allergic respiratory disease represents a significant and expanding health problem worldwide. The gold standard of therapeutic intervention is still grucocorticosteroids, although they are not effective in all patients and may cause side effects. Allergen Immunotherapy has been administrated as subcutaneous injections for treatment of allergic rhinoconjunctivitis and asthma and has been practiced for the past century. Sublingual immunotherapy (SLIT) tablets are now available for grass- or ragweed-induced rhinoconjunctivitis and will be available in Spain for house dust mite (HDM)-induced rhinoconjunctivitis and asthma in the next months...
November 13, 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29132676/interventional-therapies-for-the-treatment-of-food-allergy
#2
REVIEW
Christopher P Parrish, Edwin H Kim, J Andrew Bird
Treatment of IgE-mediated food allergies is limited to allergen avoidance and emergency treatment on accidental ingestion, which is not uncommon. In recent years, interest in interventional therapies to treat food allergy has increased significantly. Although oral, sublingual, and epicutaneous immunotherapy have shown promise in studies, none is approved as therapy for food allergy to date and questions remain regarding efficacy, safety, dosing, and duration of therapy.
February 2018: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/29130803/steroid-sparing-effect-of-sublingual-immunotherapy-real-life-study-in-mono-polisensitized-children-with-asthma
#3
Nerin Nadir Bahceciler, Nilufer Galip, Arzu Babayigit
AIM: Steroid-sparing effect of sublingual immunotherapy (SLIT) in mono/polisensitized asthmatic children were evaluated. MATERIALS AND METHODS:  Children undergoing allergen-specific SLIT between 2010 and 2014 were included. Asthma control and usage/dose of inhaled corticosteroid (ICS) in the previous year was determined. Asthma control without ICS need ≥6 months was defined as 'ICS avoidance'. RESULTS:  90 children (mean ± SD age 8...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130797/dose-finding-study-of-carbamylated-monomeric-allergoid-tablets-in-grass-allergic-rhinoconjunctivitis-patients
#4
Ralph Mösges, Christina Rohdenburg, Andrea Eichel, Gregor Zadoyan, Elena-Manja Kasche, Kija Shah-Hosseini, Walter Lehmacher, Petra Schmalz, Enrico Compalati
AIM: To determine the optimal effective and safe dose of sublingual immunotherapy tablets containing carbamylated monomeric allergoids in patients with grass pollen-induced allergic rhinoconjunctivitis. METHODS: In this prospective, randomized, double-blind, active-controlled, multicenter, Phase II study, four different daily doses were applied preseasonally for 12 weeks. RESULTS: Of 158 randomized adults, 155 subjects (safety population) received 300 units of allergy (UA)/day (n = 36), 600 UA/day (n = 43), 1000 UA/day (n = 39), or 2000 UA/day (n = 37)...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130794/allergen-immunotherapy-for-birch-apple-syndrome-what-do-we-know
#5
Cristoforo Incorvaia, Erminia Ridolo, Marina Mauro, Marina Russello, Elide Pastorello
Apple allergy is common in patients allergic to birch pollen, and this is defined as 'birch-apple syndrome'. Allergens responsible for cross-reactivity belong to the pathogenesis-related-10 family, and high homology in the amino acid sequences of the major allergens Bet v 1 from birch and Mal d 1 from apple has been demonstrated. Here we review the literature on the treatment of birch-apple syndrome by allergen immunotherapy. The only allergen immunotherapy method available thus far is based on the administration of birch-pollen extracts, through the subcutaneous or sublingual route, to induce tolerance to Bet v1 and to the homologous allergen Mal d 1...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130793/from-genomes-to-diaries-a-3-year-prospective-real-life-study-of-ragweed-specific-sublingual-immunotherapy
#6
Viktor Molnár, Adrienne Nagy, Lilla Tamási, Gabriella Gálffy, Renáta Böcskei, András Bikov, Ibolya Czaller, Zsuzsanna Csoma, Magdolna Krasznai, Csilla Csáki, Györgyi Zsigmond, Zoltán Csontos, Anikó Kurucz, Edina Kurucz, Beáta Fábos, Bálint L Bálint, Mária Sasvári-Székely, Anna Székely, Eszter Kótyuk, Gergely T Kozma, Gábor Cserta, Anita Farkas, Zsófia Gál, András Gézsi, András Millinghoffer, Péter Antal, Csaba Szalai
During the last decades, the prevalence of allergy has dramatically increased. Allergen-specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease, but there are still many questions and unmet needs hindering its widespread use to fulfill its treatment potential and maximize its benefits for the society. To provide a comprehensive phenome-wide overview in sublingual immunotherapy, using ragweed allergy as a target, we planned and carried out a longitudinal, prospective, observational, open-label study (DesensIT)...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29129888/-clinical-efficacy-of-sublingual-immunotherapy-in-the-third-treated-year-with-japanese-cedar-pollinosis-in-2017
#7
Atsushi Yuta, Yukiko Ogawa, Yusuke Suzuki, Hitomi Ogihara, Nobuo Ohta, Hideaki Kozaki, Takeshi Shimizu
It past 3 years in 2017 after the first purchase of the drug for sublingual immunotherapy (SLIT) for Japanese Cedar pollinosis (JCP). We reported the clinical efficacy of SLIT in the first and the second treated year. PURPOSE: The purpose of this study is to clear the clinical efficacy of SLIT in the third treated year by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacotherapy. METHODS: We compared the clinical efficacy in 2017, of 112 SLIT in the third treated year with 38 SCIT, 364 primary pharmacotherapy that started therapies before pollen dispersal, 254 pharmacotherapy that started therapies after pollen disposal, or 333 non-treatment...
2017: Arerugī, [Allergy]
https://www.readbyqxmd.com/read/29129887/-analysis-of-backgrounds-and-level-of-understanding-of-treatment-of-poor-adherence-and-dropout-cases-on-sublingual-immunotherapy-for-japanese-cedar-pollinosis-in-the-first-follow-up-year
#8
Sayaka Kikkawa, Atsushi Kamijo, Kazuyuki Nakagome, Tomoyuki Soma, Takehito Kobayashi, Yoshitaka Uchida, Eiji Morita, Makoto Nagata, Tomoe Inoue, Yasuhiro Kase
BACKGROUND: We considered the factors of poor adherence to and dropout from sublingual immunotherapy (SLIT) by verifying patient backgrounds 1 year after start of treatment. METHODS: We recruited 38 patients who began SLIT between November 2014 and September 2015. We analyzed their attributes and level of understanding of the treatment, and conducted a self-reported survey on factors behind dropout cases and poor adherence cases. RESULTS: Four patients dropped out 1 year after start of treatment...
2017: Arerugī, [Allergy]
https://www.readbyqxmd.com/read/29128670/synchronous-immune-alterations-mirror-clinical-response-during-allergen-immunotherapy
#9
Amedee Renand, Mohamed H Shamji, Kristina M Harris, Tielin Qin, Erik Wambre, Guy W Scadding, Peter A Wurtzen, Stephen J Till, Alkis Togias, Gerald T Nepom, William W Kwok, Stephen R Durham
BACKGROUND: Three years treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The GRASS(∗) trial demonstrated that two years treatment via either route was effective in suppressing the response to nasal allergen challenge, although was insufficient for inhibition one year after discontinuation. OBJECTIVE: To examine in the GRASS trial the time-course of immunologic changes during two years sublingual and subcutaneous immunotherapy and for one year after treatment discontinuation...
November 8, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29113525/biological-mechanisms-underlying-the-clinical-effects-of-allergen-specific-immunotherapy-in-asthmatic-children
#10
Corrado Pelaia, Alessandro Vatrella, Nicola Lombardo, Rosa Terracciano, Paolo Navalesi, Rocco Savino, Girolamo Pelaia
Allergen-specific immunotherapy (AIT) is indicated for patients with allergic asthma and/or allergic rhinitis, and can be implemented by either subcutaneous injection (SCIT) or sublingual administration (SLIT). AIT reduces asthma symptoms, lowers the use of pharmacologic controller therapy, and decreases the need for rescue medications. SLIT appears to be safer than SCIT, but SCIT seems to be more efficacious and acts earlier in allergic asthmatic children. Areas covered: This review looks at the pathobiology of allergic asthma as well as the role of regulatory T and B cells in allergen tolerance...
November 8, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29109876/debut-of-gastroesophageal-reflux-concomitant-with-administration-of-sublingual-immunotherapy
#11
Jacob Juel
Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy...
2017: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/29105313/immunological-changes-induced-in-peach-allergy-patients-with-systemic-reactions-by-pru-p-3-sublingual-immunotherapy
#12
Francisca Palomares, Francisca Gomez, Gador Bogas, Campo Paloma, James Richard Perkins, A Diaz-Perales, Maria José Rodriguez, Ana Prieto, Domingo Barber, María José Torres, Cristobalina Mayorga
SCOPE: Sublingual immunotherapy using peach extract enriched in Pru p 3 (Pru p 3-enriched-SLIT) brings a new perspective to treating patients with allergy to lipid transfer proteins. We evaluated the immunological changes induced by Pru p 3-enriched-SLIT during one year. METHODS AND RESULTS: Three groups were included: peach allergic patients who received Pru p 3-enriched-SLIT, peach allergic untreated patients and controls. Peripheral blood mononuclear cells were obtained before treatment and different time-points...
November 3, 2017: Molecular Nutrition & Food Research
https://www.readbyqxmd.com/read/29103453/clinical-applications-of-sublingual-immunotherapy
#13
REVIEW
Thomas S Edwards, Sarah K Wise
Sublingual immunotherapy (SLIT) is effective for the treatment of allergic rhinitis and allergic asthma in adults and children. In a limited number of studies, SLIT efficacy has been demonstrated for the treatment of food allergy. SLIT has a higher safety profile versus subcutaneous immunotherapy, although some systemic reactions have been reported. Appropriate patient selection, meticulous patient education, and routine follow-up are key for the safe and effective administration of SLIT. With organization and attention to detail, adding SLIT to one's practice can provide a highly valued patient service...
December 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/29072507/grass-pollen-sublingual-immunotherapy-tablets-provide-long-term-relief-of-grass-pollen-associated-allergic-rhinitis-and-reduce-the-risk-of-asthma-findings-from-a-retrospective-real-world-database-subanalysis
#14
Philippe Devillier, Ulrich Wahn, Stefan Zielen, Joachim Heinrich
BACKGROUND: We assessed real-world, long-term effectiveness of two marketed sublingual immunotherapy (SLIT) tablets for allergic rhinitis (AR), and their impact on allergic asthma (AA) onset/progression. METHODS: Retrospective, longitudinal German prescription database subanalysis of AR patients receiving 5- or 1-grass pollen SLIT tablets (n = 1,466/1,385), versus patients not using allergy immunotherapy (AIT) (n = 71,275). Primary endpoint: change over time in AR symptomatic medication prescriptions after treatment cessation; secondary endpoints: new asthma onset, and change over time in asthma medication prescriptions during treatment/follow-up periods...
November 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29070269/the-study-of-a-possible-correlation-between-serum-levels-of-interleukin-17-and-clinical-severity-in-patients-with-allergic-rhinitis
#15
Mai Aly Gharib Aly, Mohamed Tawfik El Tabbakh, Waheed Fawzy Heissam, Said Hamed Abbadi
INTRODUCTION: Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ∼20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined. AIM: To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition...
October 1, 2017: Allergy & Rhinology
https://www.readbyqxmd.com/read/29032417/clinical-evaluation-for-sublingual-immunotherapy-with-dermatophagoides-farinae-drops-in-adult-patients-with-allergic-asthma
#16
C Zhong, W Yang, Y Li, L Zou, Z Deng, M Liu, X Huang
PURPOSE: The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA. METHODS: One hundred and thirty-four adult patient data with house dust mite (HDM)-induced AA who had been treated for 2 years were collected. These patient data that we collected were divided into the SLIT group (n = 85) and control group (n = 49)...
October 14, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/29025471/enhancing-sublingual-immunotherapy-by-systemic-or-local-factors-a-role-for-vitamin-d-and-lingual-tonsil
#17
Franco Frati, Simonetta Masieri, Cristoforo Incorvaia, Serena Buttafava, Laurent Mascarell, Philippe Moingeon
No abstract text is available yet for this article.
January 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28988815/advancements-and-dilemmas-in-the-management-of-allergy
#18
REVIEW
James W Mims
Recent advances in the diagnosis and management of allergic disease also lead to new clinical decisions for providers. Advances in component (or molecular) diagnostic testing for allergy continue to build in the literature, but diagnosing inhalant allergy remains largely unchanged clinically. Prevention of allergy has been demonstrated by preventing peanut allergy in high-risk infants by intentional oral exposure to promote tolerance. Immunotherapy options have increased, with literature supporting sublingual drops, sublingual tablets, and subcutaneous immunotherapy...
December 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/28964530/efficacy-and-safety-of-subcutaneous-and-sublingual-immunotherapy-for-allergic-rhinoconjunctivitis-and-asthma
#19
REVIEW
Christopher R Roxbury, Sandra Y Lin
Allergic rhinitis is often associated with asthma and has significant impacts on health care costs and productivity in the United States. Although allergen avoidance and pharmacotherapy are effective, allergen-specific immunotherapy is the only treatment that may lead to improved allergy symptoms even after treatment is discontinued. Subcutaneous immunotherapy has been the mainstay of allergen-specific immunotherapy in the United States for decades, but sublingual immunotherapy has recently become available...
September 27, 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/28964529/advances-in-food-allergy
#20
REVIEW
Christine B Franzese
Food allergy has been increasing in prevalence for the last few decades, and numerous studies have evaluated ways of improving the allergy practitioner's ability to accurately diagnose patients who are truly food allergic, rather than sensitive but able to tolerate food. Once diagnosed, the current standard treatment is food elimination and avoidance, but other potential treatment options like oral immunotherapy, sublingual immunotherapy, and epicutaneous immunotherapy are becoming promising alternatives. Due the health care costs and potential for life-threatening adverse reactions, much attention has been given to the prevention of food allergies, resulting a shift in recent guideline recommendations...
September 27, 2017: Otolaryngologic Clinics of North America
keyword
keyword
1712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"